| Literature DB >> 27144492 |
Laetitia Yperzeele1,2, Robbert-Jan van Hooff2,3, Ann De Smedt2,3, Guy Nagels2,3,4, Ives Hubloue5,6, Jacques De Keyser2,3,7, Raf Brouns2,3.
Abstract
BACKGROUND: Heart rate variability (HRV) is a parameter of autonomic nervous system function. A decrease of HRV has been associated with disease severity, risk of complications and prognosis in several conditions.Entities:
Mesh:
Year: 2016 PMID: 27144492 PMCID: PMC4856404 DOI: 10.1371/journal.pone.0154834
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of HRV acquisition during ambulance transportation.
HRV was registered in 50 controls. Three registrations were excluded from analysis: one because of technical reasons and 2 because of non-sinus rhythm. HRV parameters were analyzed in 47 controls, matched to the patient population for age and gender (S2 Table).
Reliability of in-ambulance HRV parameters.
| Pearson’s | Cronbach’s α | ICC | LOA | ||
|---|---|---|---|---|---|
| TINN (ms) | 0.897 | 0.946 | 0.945 | 0.947 | -96.09–93.81 |
| LF/HF ratio | 0.730 | 0.844 | 0.821 | 0.820 | -12.35–10.22 |
| SampEn | 0.628 | 0.772 | 0.770 | 0.774 | -1,30–1,21 |
| DFA α1 | 0.818 | 0.900 | 0.899 | 0.901 | -0.49–0.49 |
| LF/HF ratio | 0.719 | 0.837 | 0.835 | 0.839 | -6.87–6.99 |
Abbreviations: DFA, detrended fluctuation analysis; HRV, heart rate variability; ICC, intraclass correlation coefficient; LF/HF ratio, low frequency/high frequency ratio; LOA, 95% limits of agreement; rhh, half-test reliability coefficient; SampEn, Sample Entropy; TINN, triangular interpolation of the NN interval histogram.
Fig 2Bland-Altman plots with 95% limits of agreement for key HRV indices.
Bland-Altman diagrams showing the mean differences ± 2 SD between measurement HRV F1 and F2.
HRV parameters in patients and controls*
| Patient group | Control group | ||
|---|---|---|---|
| mean HR | 97 (21) | 75 (13) | |
| TINN (ms) | 81.45 (IQR 54.40–133.97) | 128.40 (88.60–179.40) | |
| LF/HF ratio | 1.320 (0.609–3.692) | 2.480 (1.469–4.138) | |
| SampEn | 1.839 (1.189–2.289) | 1.762 (1.542–2.036) | |
| DFA α1 | 1.084 (SD 0.420) | 1.262 (SD 0.279) | |
| LF/HF ratio | 1.117 (0.575–3.509) | 2.155 (1.085–4.162) | |
* Data given as median (interquartile range) or mean (standard deviation);
# Mann-Whitney U test;
° Student t test.
Abbreviations: DFA, detrended fluctuation analysis; HR, heart rate; HRV, heart rate variability; LF/HF ratio, low frequency/high frequency ratio; SampEn, Sample Entropy; TINN, triangular interpolation of the NN interval histogram.
Baseline characteristics patient population*.
| Favorable outcome | Unfavorable outcome | ||
|---|---|---|---|
| Male gender | 13 (54.2%) | 19 (38.0%) | |
| Age (years) | 64.9 (48.1–82.3) | 72.4 (60.0–85.3) | |
| GCS | 15 (14–15) | 15 (12–15) | |
| SBP (mmHg) | 157 (31) | 159 (25) | |
| DBP (mmHg) | 88 (19) | 92 (16) | |
| MAP (mmHg) | 111 (21) | 114 (17) | |
| HR (bpm) | 95 (18) | 95 (26) | |
| spO2 (%) | 97 (95–98) | 96 (91–98) | |
| Glycaemia (mg/dl) | 147 (104–188) | 120 (99–211) | |
| Arterial hypertension | 9 (37.5%) | 7 (46.7%) | |
| Active smoking | 2 (8.3%) | 4 (26.7%) | |
| Former smoking | 2 (8.3%) | 4 (26.7%) | |
| Diabetes mellitus | 11 (45.8%) | 3 (20.0%) | |
| Atrial fibrillation | 3 (12.5%) | 2 (13.3%) | |
| Acute myocardial infarction | 3 (12.5%) | 1 (6.7%) | |
| Coronary artery disease | 2 (8.3%) | 3 (20.0%) | |
| Peripheral artery disease | 1 (4.2%) | 0 (0.0%) | |
| Stroke | 3 (12.5%) | 0 (0.0%) | |
| Dyslipidemia | 7 (29.2%) | 5 (33.3%) | |
| Obstructive sleep apnea | 0 (0.0%) | 2 (13.3%) | |
| Migraine | 0 (0.0%) | 1 (2.1%) | |
| Thyroid disease | 3 (12.5%) | 2 (13.3%) | |
| Obesity | 0 (0.0%) | 1 (6.7%) | |
| Epilepsy | 3 (12.5%) | 0 (0.0%) | |
| Beta-blocker | 2 (8.3%) | 3 (20.0%) | |
| Central agonist | 1 (4.2%) | 0 (0.0%) | |
| Calcium channel blocker | 4 (16.7%) | 2 (13.3%) | |
| ACE inhibitor | 4 (16.7%) | 1 (6.7%) | |
| Angiotensin II receptor blocker | 2 (8.3%) | 2 (13.3%) | |
| Other antihypertensive agent | 4 (16.7%) | 4 (26.7%) | |
| Anti-arrhythmic agent | 1 (4.2%) | 1 (6.7%) | |
| Sympathicomimetic | 2 (8.3%) | 3 (20.0%) | |
| Statin | 7 (29.2%) | 4 (26.7%) | |
| Anticoagulant | 3 (12.5%) | 0 (0.0%) | |
| Antiaggregant | 8 (33.3%) | 5 (33.3%) | |
| Thyroid hormone | 2 (8.3%) | 2 (13.3%) | |
| Morfinomimetic drug | 4 (16.7%) | 3 (20.0%) | |
| Morphinomimetic | 3 (12.5%) | 1 (6.7%) | |
| Anticholinergic | 1 (4.2%) | 2 (13.3%) | |
| Sympathicomimetic | 1 (4.2%) | 2 (13.3%) | |
| Anticoagulant | 0 (0.0%) | 1 (6.7%) | |
| Antiaggregant | 1 (4.2%) | 1 (6.7%) | |
| Mean HR | 98 (18) | 97 (25) | |
| TINN | 80.85 (58.52–143.12) | 81.30 (44.00–122.80) | |
| FD LF/HF ratio | 1.578 (0.899–3.531) | 0.711 (0.335–3.168) | |
| SampEn | 1.403 (0.928–2.183) | 2.053 (1.527–2.557) | |
| DFA α1 | 1.187 (0.396) | 0.895 (0.409) | |
| TF LF/HF ratio | 1.827 (0.950–4.069) | 0.603 (0.385–3.771) | |
* Data given as number (percentage), mean (SD) or as median (interquartile range);
§ Fisher’s exact test;
# Mann-Whitney U test;
° Student t test.
Abbreviations: DFA, detrended fluctuation analysis; FD LF/HF, low frequency/high frequency ratio in the frequency domain; HRV, heart rate variability; SampEn, Sample Entropy; TINN, triangular interpolation of the NN interval histogram; TF LF/HF, low frequency/high frequency ratio in the time domain.